Hello fellow investors / traders,

 

All systems are go in Arch Therapeutics Inc (ARTH) today. It is tapping on the door of its 52 week high of $0.54, with a close yesterday of $0.43 there is still a ton of upside.

Barchart.com, one of our favorite investing due diligence sites ranks ARTH as a  -> -> ->

It's a no brainer really. Huge volume, awesome news coming from the company and perfect technical's make this a strong potential winner.

The only thing we need to do is to be active at the open. Two possible schools of thought here...

One, ARTH runs out of the gate on continuation from its perfect technical bounce the past couple of days.

Or two, there is some profit taking at the opening followed by a bounce and then resumes its push towards its 52 week highs.

Either way, we need to be watching this carefully and be ready to pounce when the time comes.

If you missed my report on ARTH last night, I've included it below for your reading pleasure.

Make sure you are ready in roll in just a couple hours.

ShiznitStocks.com

 

Hello fellow investors / traders,

We have a special breakout play on tap. Arch Therapeutics Inc (ARTH) is a monster breakout trade that we have to take a very close look at tomorrow.

ARTH recently made a strong surge higher on massive volume and then pulled backed to its 61.8% fib retracement level where it bounced perfectly.

As you can see in the chart below, the pullback on Friday also bounced perfectly off the 50 day moving average. Today was a "consolidation" day, and we think the bounce continues tomorrow on its way to retest recent highs.

We think this pullback and subsequent bounce could be the perfect entry for those who missed the initial run higher.





Arch Therapeutics, Inc. (ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures

ARTH specializes in developing novel approaches to the problem of bleeding (hemostasis) and leaking (sealant) during surgery and trauma care.  Both issues are a major concern for health professionals that have to deal with more than 53 million surgical procedures in the US annually. An estimated 1.14% of those surgical procedures result in death and whilst that percentage may seem small, it translates to roughly 604,000 deaths annually.

Less effective products exist in this arena to stop bleeding and prevent fluid-loss, but none offer the speed of the AC5™ . The closest competing product according to ARTH is capable of an average time to hemostasis of 180 seconds. Whereas the AC5™ stops surgical bleeding in 10 seconds on average. This makes the product particularly unique in a space that desperately needs effective solutions.

ARTH is poised to become a major play in a medical device market $133 billion US medical device market.

To learn more about ARTH, visit their website http://www.archtherapeutics.com/


In December last year, ARTH announced it had been given clearance to initiate a clinical trial in Europe.

“The randomized controlled single-blind investigation is designed to assess safety and performance of AC5™ in bleeding wounds created during the course of a dermatological procedure in fewer than 50 patients,” said the report.

"This is an important milestone for the Company as we continue to bring AC5™  and our technology platform another step closer to market. We expect to apply for a CE Mark if the data from our study is supportive. We remain committed to completing subsequent clinical trials and expanding the indications for product use," said ARTH President & CEO Dr. Terence Norchi.

And just last week ARTH announced that it has received a notice of allowance from the U.S. Patent Office for a broad method-of-use patent that covers systemically administering the Company's self-assembling technology for treating damaged extracellular matrix and leaky tight junctions.

ARTH has made significant groundbreaking progress in a short period of time, and the breakout chart shows how much investors love it.

We think this pullback and bounce is an excellent opportunity to enter the trade as it looks to retest recent highs. 

Make sure you get ARTH on your radar tonight, do your research, and be ready for the opening bell.

I'll be back in the morning with a further update.